The Pathological Assessment of Total Mesorectal Excision: What Are the Relevant Resection Margins?
|
|
|
- Adela Armstrong
- 10 years ago
- Views:
Transcription
1 The Pathological Assessment of Total Mesorectal Excision: What Are the Relevant Resection Margins? Frank Autschbach F. Autschbach ( ) Institute of Pathology, Heidelberg University, Im Neuenheimer Feld 220/221, Heidelberg, Germany [email protected] Abstract An accurate pathological reporting of rectal cancer specimens has important implications concerning patients prognosis and further clinical management. Since locoregional recurrence and prognosis in rectal cancer is especially influenced by the extent of extramural tumor spread into the mesorectal lymphovascular fatty tissue, systematic investigation of the status of the circumferential mesorectal resection margin is a point of major importance to determine the completeness of tumor resection. Careful macroscopic assessment of the resection specimen should be performed to monitor the quality of mesorectal excision. Introduction Locoregional recurrence and distant metastasis are two major factors which determine a patient s prognosis following curative resection of rectal cancer. While the occurrence of distant metastasis can only indirectly be influenced by surgery and is largely determined by tumor-related factors such as tumor grade and stage, the principal aim of surgical treatment is the prevention of local recurrent disease. Recurrent tumor growth often occurs within the first two years after the operation and mostly presents as a pelvic mass within the excised tumor bed. A number of studies suggest that a major cause of such recurrences is a failure of complete local removal of the tumor. In this context, the quality of the operative procedure performed by the individual surgeon represents one of the most important prognostic factors (Hermanek et al. 1989, 1994, 1995; Hohenberger et al. 1998; Köckerling 1988). The concept of total mesorectal excision (TME), introduced by Heald et al. (Heald et al. 1982; Heald and Ryall 1986), constituted important progress in thesurgicaltreatmentofrectalcancer.tmeconsistsofacompleteremovalof the rectum together with its surrounding mesorectal lymphovascular fatty tissue (mesorectum) by precise sharp dissection along the visceral pelvic fascia ( holy plane ) (Heald 1988), to minimize the residual tumor load. It has been shown that Recent Results in Cancer Research, Vol. 165 c Springer-Verlag Berlin Heidelberg 2005
2 The Pathological Assessment of Total Mesorectal Excision: What Are the Relevant Resection Margins? 31 careful adherence to this procedure can significantly reduce the rate of locoregional recurrences in rectal cancer. Types of Resection Margins in Rectal Cancer Specimens An accurate pathological reporting of rectal cancer resection specimens has important implications for the clinical management and the individual prognosis of the patient. The determination of the completeness of tumor resection is based on the assessment of resection margins by the pathologist. Principal sites which must be considered are the proximal and distal resection margins as well as the deep antiluminal (mesorectal) margin within the plane of dissection, called the lateral, radial, or circumferential resection margin (CRM). Proximal Resection Margin Due to the relatively wide proximal safety distance in most rectal cancer specimens (length of resected gut proximal to the tumor usually >15 cm, proximal ligation of the inferior mesenterial artery), involvement of the proximal resection margin by tumor is exceptionally rare. Therefore, this site is generally nonproblematic. Distal Intramural Resection Margin The distal resection margin in rectal cancer specimens is more critical, depending on the localization of the tumor (distance from the dentate line). With regard to the question of an adequate distal tumor clearance, two different aspects must be considered: intramural as well as extramural distal tumor spread, including lymphatic spread. Concerning the former type of spread, it has been shown that distal intramural extension is rather uncommon in rectal carcinoma (Shirouzu et al. 1995). In over 95% of cases it is limited to a length of about 1 to 2 cm distal to the endoluminally visible tumor. A distal mural safety margin in this range can thus be considered appropriate for most cases (Maurer et al. 1999; Pollett and Nicholls 1983; Riedl et al. 1995; Shirouzu et al. 1995; Williams et al. 1983). It should be kept in mind that formaldehyde fixation induces a significant shrinkage of the bowel (about twofold), which might result in an underestimation of the length of distal tumor clearance (Goldstein et al. 1999; Hermanek and Gall 1981; Kwok et al. 1996). It is recommended to take measurements on the freshly obtained, native specimen (if possible) and/or to pin the tissue on corkboard before fixation to minimize shrinkage. If the tumor macroscopically approaches the distal mural margin of the specimen, frozen section diagnostics might be considered for pathohistological assessment. Using such precautions, direct involvement of the distal intramural resection margin by tumor is a rare event (Birbeck et al. 2002; Ng et al. 1993). It is noteworthy that even a narrow range of distal mural clearance has no adverse influence on locoregional recurrence rates. However, if distal mural extension is
3 32 Frank Autschbach prominent, it is usually associated with a locally advanced tumor stage and poor long-term prognosis, which is largely determined by the occurrence of distant metastasis rather than local recurrence (Pollett and Nicholls 1983; Philips et al. 1984; Shirouzu et al. 1995; Vernava and Moran 1992, Williams et al. 1983). Circumferential Resection Margin One important aspect concerning the growth pattern of rectal carcinoma is its tendency for extramural radial spread into the mesorectal lymphovascular fatty tissue. Radial tumor spread may be continuous and expansive, displaying a pushing type of the invasive margin (Fig. 1), but not rarely (>20%) also includes irregular, infiltrative, and discontinuous modes of spread with tumor deposits extending to the CRM and/or the serosa (Fig. 2). It has been shown that an infiltrative patternofgrowthiscorrelatedwithpoorprognosisincolorectalcancer(jassetal. 1986) and constitutes an adverse prognostic factor which is independent of tumor stage (Compton et al. 2000). By histology, various often co-existing modes of extramural tumor spread occur, including continuous and discontinuous infiltrates within the perirectal fatty tissue, extramural venous invasion, lymphangiosis carcinomatosa and lymph node metastasis (Fig. 3). Although most mesorectal tumor deposits are located at the level of or proximal to the cancer, discontinuous extra- Figure 1. Rectal adenocarcinoma of the expansive type displaying a rather well defined invasive tumor margin. Tumor formations (gray-white color) infiltrate the mesorectal fatty tissue (pt3), but do not approach the circumferential (mesorectal) resection margin
4 The Pathological Assessment of Total Mesorectal Excision: What Are the Relevant Resection Margins? 33 Figure 2A, B. Adenocarcinoma of the infiltrative type displaying an irregular and discontinuous mode of spread with extramural tumor deposits extending to the circumferential resection margin (bottom) and to the lateral serosal aspects (left and right) of this specimen (rectosigmoid)
5 34 Frank Autschbach Figure 3A F. Histopathological modes of mesorectal tumor spread in rectal adenocarcinoma. A Continuous spread. B Discontinuous mesorectal deposits. C Extramural venous invasion. D Lymph node metastasis. E Lymphangiosis carcinomatosa in the immediate vicinity of the circumferential resection margin (bottom). F Direct involvement of the circumferential resection margin. H&E stains
6 The Pathological Assessment of Total Mesorectal Excision: What Are the Relevant Resection Margins? 35 Figure 4. Intra- and extramural spread in rectal cancer mural tumor spread has been shown to involve also regions distal (up to 4 cm) to the main tumor mass (>10%) (Heald and Ryall 1986; Scott et al. 1995) (Fig. 4). The demonstration of significantly reduced local recurrence rates and increased patient survival after total mesorectal excision for rectal cancer (Heald et al. 1982, 1998; Heald and Ryall 1986; Heald et al. 1998; Hohenberger et al. 1998; Kapiteijn et al. 2001; Köckerling et al. 1998; MacFarlane et al. 1993; Wibe et al. 2002) strongly indicate that recurrence is mainly caused by an inadequate resection of extramural tumor deposits within the mesorectal lymphovascular fatty tissue using standard surgical procedures. One of the basic reports demonstrating the importance of lateral tumor spread and the prognostic significance of CRM involvement in rectal cancer was published in 1986 by Quirke and colleagues. They investigated a series of 52 rectal carcinomas (operated by standard procedures) where they embedded the whole tumor area after serial transverse slicing of the specimens. The extent of mesorectal spread was determined, including morphometric measurements. The outer limit of the tumor was defined as the most lateral penetration of the mesorectum, either by continuous or discontinuous tumor extension. An involvement of the CRM was considered when tumor directly infiltrated the CRM or reached this margin within a distance of less than 1 mm (Quirke et al. 1986; Quirke and Dixon 1988). The CRM was involved in 27% of the cases investigated in that study. Most importantly, those authors found that CRM involvement was associated with a local recurrence rate of 85%, in contrast to a recurrence rate of only 3% in the group of CRM-negative cases (median follow-up: 23 months). Involvement of the CRM was associated with increasing Dukes stage, decreasing tumor differentiation, and an infiltrative tumor margin. In a further study on 141 cases, these results were confirmed (Adam et al. 1994). Tumor involvement of the CRM was seen in 25% of cases with potentially curative resection, and the frequency of local recurrence was again significantly higher in CRM-positive cases compared to CRM-negative cases (78% vs. 10%, respectively; median follow-up, 5 years). The authors performed a multivariate analysis of several pathological variables and demonstrated that an involvement of the CRM is one of the most important factors independently influencing both local recurrence and survival.
7 36 Frank Autschbach The important prognostic significance of the circumferential margin status in rectal cancer has been confirmed independently by other groups (Cawthorn et al. 1990; DeHaas-Kock 1996; Ng et al. 1993). In a recent follow-up study from Leeds, UK (Birbeck et al. 2002), the investigators could formally validate that a tumor distance of 1 mm or less to the CRM is associated with a significantly increased riskoflocalrecurrence.allmajormodesoftumorspreadcontributedtothis increased risk, except for a CRM involvement by tumor deposits within a lymph node, a result which has also been confirmed by others (Nagtegaal et al. 2002). Since total mesorectal excision was not systematically performed in the series mentioned above, the relevance of CRM involvement in patient subgroups treated exclusively by TME has been debated. A recent study by the Norwegian Rectal Cancer Group addressed this point in a series of 686 patients who underwent TME (Wibe et al. 2002). Although the overall recurrence rate and the percentage of CRM involvement were comparably reduced (7% and 9.5%, respectively), this study proved that involvement of the CRM by a distance of 1 mm or less is associated with significantly higher rates of locoregional recurrence, distant metastasis, and tumor-related death, even after TME (22% recurrence in CRM-positive vs. 5% in CRM-negative cases; exponential increase with decreasing CRM). A further recent study from the Netherlands independently confirmed that CRM involvement in TME-treated patients is of prognostic significance with regard to local recurrence (especially TNM stage III patients), distant metastasis, and survival (Nagtegaal et al 2002). Those authors found that a tumor distance of less than 2 mm from the circumferential margin is already associated with a significantly increased recurrence risk and should be considered a CRM involvement. Macroscopic Assessment of Mesorectal Excision Since the introduction of TME surgery, it has become clear that considerable regional differences exist between surgical departments with regard to the oncological quality of resection as well as local recurrence rates. In this context, it has been proposed that a macroscopic assessment of the mesorectal excision should be included in pathology reports to monitor the surgical practice (Hermanek et al. 2003). Due to the problem of distal mesorectal spread, carcinomas of the middle and lower thirds of the rectum require a total excision of the mesorectum down to the pelvic floor. A partial TME can be considered for the treatment of carcinomas of the upper third, provided that the mesorectum is transected at least 3 cm distal to the aboral margin of the tumor (measured on the fresh non-stretched specimen, corresponding to an in situ distance of about 5 cm) and has a right-angled configuration of the transection line (avoidance of so-called coning of the mesorectum). Concerning the circumferential aspect, an optimal/complete mesorectal excision is characterized by a good bulk of mesorectum with a smooth, lipoma-like surface with no or only minor defects/incisions (not deeper than 5 mm). Suboptimal/nearly complete excisions have a moderate bulk of mesorectum with a slightly irregular surface, circumscript defects, and probably some minor degree of coning. Incomplete mesorectal excisions of poor quality are characterized by a little bulk
8 The Pathological Assessment of Total Mesorectal Excision: What Are the Relevant Resection Margins? 37 of mesorectum with a highly irregular surface, larger defects (>1 cm 2 ), or deep incisions down onto the muscularis propria and/or prominent coning (Hermanek et al. 2003; Nagtegaal and Van Krieken 2002; Nagtegaal et al. 2002; Quirke 1998). The evaluation of surface defects is facilitated by serial transverse slicing of the tumor area (photodocumentation is recommended) and might be supplemented by recently published stain marking techniques (Sterk et al. 2000). Concerning the relevance of such type of assessment, a recent study on 180 cases by the Dutch Colorectal Cancer Group (Nagtegaal et al. 2002) could demonstrate that incomplete mesorectal excision is related to advanced T-stages and is associated with a high incidence of CRM involvement (>40%). However, even in cases without demonstrated CRM involvement, significant differences in outcome between cases with a complete/nearly complete versus incomplete mesorectum were observed. These results indicate a prognostic relevance of this macroscopic parameter, which should be investigated in more detail in future studies. Conclusions The pathological reporting of rectal cancer resection specimens should adhere to standardized protocols. The quality of mesorectal excision and the status of the circumferential resection margin should receive special attention (Fig. 5). Such information has important implications concerning a patient s prognosis and further clinical management. Figure 5. Pathological reporting of rectal carcinoma
9 38 Frank Autschbach References Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P (1994) Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 344: Birbeck KF, Macklin CP, Tiffin MJ, Parsons W, Dixon MF, Finan PJ, Johnston D, Quirke P (2002) Rates of circumferential margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg 235: Cawthorn SJ, Parums DV, Gibbs NM, A Hern RP, Caffarey SM, Broughton CIM, Marks CG (1990) Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet 335: Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP (2000) American Joint committee on cancer prognostic factors consensus conference colorectal working group. Cancer 88: DeHaas-Kock DFM, Baeten CGMI, Jager JJ, Langendijk JA, Schouten LJ, Volovics A, Arends JW (1996) Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg 83: Hall NR, Finan PJ, Al-Jaberi T, Tsang CS, Brown SR, Dixon MF, Quirke P (1998) Circumferential margin involvement after mesorectal excision of rectal cancer with curative intent. Predictor of survival but not local recurrence? Dis Colon Rectum 41: Goldstein N, Soman A, Sacksner J (1999) Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. Anat Pathol 111: Heald RJ (1988) The holy plane of rectal surgery. J Royal Soc Med 81: Heald RJ, Ryall RDH (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1: Heald RJ, Husband EM, Ryall RDH (1982) The mesorectum in rectal cancer surgery the clue to pelvic recurrence? Br J Surg 69: Heald RJ, Moran BJ, Ryall RDH, Sexton R, MacFarlane JK (1998) Rectal cancer. The Basingstoke experience of total mesorectal excision, Arch Surg 133: Hermanek P, Gall FP (1981) Der aborale Sicherheitsabstand bei der sphinctererhaltenden Rektumresektion. Chirurg 52:25 29 Hermanek P, Guggenmoos-Holzmann, Gall FP (1989) Prognostic factors in rectal carcinoma. A contribution to the further development of tumor classification. Dis Colon Rectum 32: Hermanek P, Wiebelt H, Riedl S, Staimmer D, Hermanek P, und die Studiengruppe Kolorektales Karzinom (SGKRK) (1994) Langzeitergebnisse der chirurgischen Therapie des Coloncarcinoms. Ergebnisse der Studiengruppe Kolorektales Karzinom (SGKRK). Chirurg 65: Hermanek P, Wiebelt H, Staimmer D, Riedl S, and the German Study Group Colo-Rectal Carcinoma (SGCRC) (1995) Prognostic factors of rectum carcinoma experience of the German multicentre study SGCRC. Tumori 81 Supplement:60 64 Hermanek P, Hermanek P Hohenberger W, Klimpfinger M, Köckerling F, Papadopoulos T (2003) The pathological assessment of mesorectal excision: implications for further treatment and quality management. Int J Colorectal Dis 18: Hohenberger W, Schick CH, Göhl J (1998) Mesorectal lymph node dissection: is it beneficial? Langenbeck s Arch Surg 383: Jass JR, Atkin WS, Cuzick J, Bussey HJ, Morson BC, Northover JM, Todd IP (1986) The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 10: Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJT, Pahlmann L, Glimelius B, Van Krieken HJM, Leer JWH, Van de Velde CJH, for the Dutch Colorectal Cancer Group (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345: Köckerling F, Reymond MA, Alterdorf-Hofmann A, Dworak O, Hohenberger W (1988) Influence of Surgery on metachronous distant metastases and survival in rectal cancer. J Clin Oncol 16: Kwok SPY, Lau WY, Leung KL, Liew CT, Li AKC (1996) Prospective analysis of the distal margin of clearance in anterior resection for rectal carcinoma. Br J Surg 83: Maurer CA, Renzulli P, Meyer JD, Büchler MW (1999) Rektumkarzinom. Optimierung durch partielle oder totale Mesorektumentfernung. Zentralbl Chir 124:
10 The Pathological Assessment of Total Mesorectal Excision: What Are the Relevant Resection Margins? 39 MacFarlane JK, Ryall RDH, Heals RJ (1993) Mesorectal excision for rectal cancer. Lancet 341: Nagtegaal ID, Van Krieken JHJM (2002) The role of the pathologist in the quality control of diagnosis and treatment of rectal cancer an overview. Eur J Cancer 38: Nagtegaal ID, Marijnen CAM, Kranenbarg EK, Van de Velde CJH, Van Krieken JHJM, for the Pathology Review Committee and the Cooperative Clinical Investigators (2002) Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma. Not one millimeter but two millimeters is the limit. Am J Pathol 26: Nagtegaal ID, Van de Velde CJH, Van der Worp E, Kapiteijn E, Quirke P, Van Krieken JHJM, and the Pathology Review Committee for the Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group (2002) Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 20: Ng IOL, Luk ISC, Yuen ST, Lau PWK, Pritchett CJ, Ng M, Poon GP, Ho J (1993) Surgical lateral clearance in resected rectal carcinomas. A multivariate analysis of clinicopathologic features. Cancer 71: Phillips RKS, Hittinger R, Blesovsky L, Fry JS, Fielding LP (1984) Local recurrence following curative surgery for large bowel cancer: II. The rectum and rectosigmoid. Br J Surg 71:17 20 Pollett WG, Nicholls RJ (1983) The relationship between the extent of distal clearance and survival and local recurrence rates after curative anterior resection for carcinoma of the rectum. Ann Surg 198: Quirke P (1998) The pathologist, the surgeon and colorectal cancer-get it right because it matters. Progress Pathol 4: Quirke P, Dixon MF (1988) How I do it. The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. Int J Colorect Dis 3: Quirke P, Durdey P, Dixon MF, Williams NS (1986) Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 2: Riedl S, Wiebelt H, Bergmann U, Hermanek P (1995) Postoperative Komplikationen und Letalität in der chirurgischen Therapie des Coloncarcinoms. Ergebnisse der deutschen Multizenterstudie der Studiengruppe Kolorektales Karzinom (SGKRK). Chirurg 66: Scott N, Jackson P, Al-Jaberi T, Dixon MF, Quirke P, Finan PF (1995) Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer. Br J Surg 82: Shirouzu K, Isomoto H, Kakegawa T (1995) Distal spread of rectal cancer and optimal distal margin of resection for sphincter-preserving surgery. Cancer 76: Vernava AM, Moran M (1992) A prospective evaluation of distal margins in carcinoma of the rectum. Surg Gynecol Obstet 163: Wibe A, Eriksen MT, Syse A, Myrvold HE, Soreide O. on behalf of the Norwegian Rectal Cancer Group (2002) Total mesorectal excision for rectal cancer what can be achieved by a national audit? Colorectal Disease 5: WibeA,RendedalPR,SvenssonE,NorsteinJ,EideTJ,MyrvoldHE,SoreideO,onbehalfof the Norwegian Rectal Cancer Group (2002) Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 89: Williams NS, Dixon MF, Johnston D (1983) Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients survival. Br J Surg 70:
GENERAL SUMMARY AND DISCUSSION
GENERAL SUMMARY AND DISCUSSION In the last 30 years, abdominal surgery has progressed from the standard open approach to less invasive techniques such as laparoscopy and natural orifice translumenal endoscopic
Pathological assessment of the rectal cancer resection specimen
P R A C T I C E G U I D E L I N E S Pathological assessment of the rectal cancer resection specimen Authors Key words A. Hoorens, M. De Ridder, A. Jouret-Mourin, C. Sempoux, C.A. Cuvelier, N. Nagy, G.
What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer? Iris D. Nagtegaal and Phil Quirke
VOLUME 26 NUMBER 2 JANUARY 10 2008 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer? Iris D. Nagtegaal and
Chapter 5. Eur J Cancer 2009; 45: 1175-1183
Chapter 5 The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer Marcel
Stadards in Abdominoperineal Resection
Stadards in Abdominoperineal Resection Manuel Francisco T. Roxas, MD, FPCS, FPSCRS, FACS Clinical Associate Professor, University of the Philippines Chief, Section of Colorectal Surgery, Department of
How to report Upper GI EMR/ESD specimens
Section of Pathology and Tumour Biology How to report Upper GI EMR/ESD specimens Dr.H.Grabsch Warning. Most of the criteria, methodologies, evidence presented in this talk are based on studies in early
MRI in Rectal Cancer. Kartik S Jhaveri, MD,FRCPC Director, Abdominal MRI Director, CME Program
MRI in Rectal Cancer Kartik S Jhaveri, MD,FRCPC Director, Abdominal MRI Director, CME Program DISCLOSURES No Relevant Disclosures 2 OBJECTIVES Imaging of Rectal Cancer Why MRI? MR Protocol MR Anatomy Preoperative
Approccio multidisciplinare nei tumori del retto
Approccio multidisciplinare nei tumori del retto F. Muñoz Radiation Oncology Department University of Torino, Italy RECENT CHANGES IN RECTAL CANCER DIAGNOSIS AND THERAPY Optimal staging by EUS and MRI
Bridging Techniques. What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS
Bridging Techniques What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS Associate Professor of Surgery Assistant Program Director, General Surgery Residency Disclosures
EMR Can anyone do this?
EMR Can anyone do this? Norio Fukami, MD University of Colorado Piecemeal resection? 1 Endoscopic mucosal resection (EMR) and Endoscopic submucosal dissection (ESD) Endoscopic removal of premalignant or
Neoadjuvant therapy are we doing it right? Short course and chemoradiation
Neoadjuvant therapy are we doing it right? Short course and chemoradiation Rob Glynne-Jones Mount Vernon Cancer Centre Relevant Endpoints in rectal cancer Local recurrence Disease-free survival Overall
How to treat early gastric cancer. Surgery
How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies
The evolution of rectal cancer therapy. Objectives
The evolution of rectal cancer therapy Hagen Kennecke MD MHA FRCPC Western Canada Consensus Conference September 5, 2014 Objectives Identify standard therapy: stage II/III rectal cancer Update recent adjuvant
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
The Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum
The Royal Marsden Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum Any surgeon can cure Surgeon - dependent No surgeon can cure EMR D2 GASTRECTOMY H N SN. WEDGE
Rectal Cancer. To Radiate or not to radiate? Q: Should rectal cancer RT/CRT decisions be based solely on stage? 11/09/2014
Rectal Cancer To Radiate or not to radiate?? Dr. Corinne Doll Radiation Oncologist Tom Baker Cancer Centre Calgary, Alberta Q: Should rectal cancer RT/CRT decisions be based solely on stage? 1 Q: Can RT/CRT
National Bowel Cancer Audit Report 2008 Public and Executive Summary
National Bowel Cancer Audit Report 2008 Public and Executive Summary Prepared in association with: Healthcare Quality Improvement Partnership HQIP Association of Coloproctology of Great Britain and Ireland
J Clin Oncol 28:264-271. 2009 by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 2 JANUARY 1 21 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data Leonard L. Gunderson, John Milburn
A912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
Current Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande
PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY Dr. Shailesh V. Shrikhande Associate Professor & Consultant Surgeon GI and HPB Surgical Oncology Tata Memorial Hospital, Mumbai INDIA HELICAL
Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins
The American Journal of Surgery 190 (2005) 521 525 George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald,
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding
Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
Diagnosing vascular (venous) invasion in colorectal carcinomas
Diagnosing vascular (venous) invasion in colorectal carcinomas Improving reproducibility and potential pitfalls Gábor Cserni Bács-Kiskun County Teaching Hospital, Kecskemét & University of Szeged Hungary
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
OBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
PROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL
Oncoplastic breast conservation surgery Melvin J Silverstein C H A P T E R 5 Introduction Oncoplastic breast conservation surgery combines oncologic principles with plastic surgical techniques. But it
Loco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
HER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
ESD for colorectal lesions I am in favour. Alessandro Repici, MD Digestive Endoscopy Unit IRCCS Istituto Clinico Humanitas Milano, Italy
ESD for colorectal lesions I am in favour Alessandro Repici, MD Digestive Endoscopy Unit IRCCS Istituto Clinico Humanitas Milano, Italy Surgery for early colonic lesions 51 pts referred for lap colectomy
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
The Staging of Colorectal Cancer: What s New in the Seventh Edition of The AJCC Cancer Staging Manual
The Staging of Colorectal Cancer: What s New in the Seventh Edition of The AJCC Cancer Staging Manual J. Milburn Jessup, MD Chief, Diagnostics Evaluation Branch Cancer Diagnosis Program, DCTD National
Standards and datasets for reporting cancers. Dataset for colorectal cancer histopathology reports. July 2014
Standards and datasets for reporting cancers Dataset for colorectal cancer histopathology reports July 2014 Authors: Dr Maurice B Loughrey, Consultant Pathologist, Royal Victoria Hospital, Belfast Trust,
Evidence tabel Lokaal palliatieve behandelingen
Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014 Prof. Dr. Chris Verslype, Leuven Prof. Dr. Aurel Perren, Bern Menue Challenges: 1. Gastric NET 2. Appendiceal NET 3. Rectal NET SEER,
Cancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
ductal carcinoma in situ (DCIS)
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
Update on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
Luis D. Carcorze Soto, MD PGY-3
Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:
PET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
PROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
Understanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
Does my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: [email protected] Prostate Cancer Classifier
Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
Endoscopic Submucosal Dissection (E.S.D.) vs. Endoscopic Mucosal Resection (E.M.R.) in Colombia. Advocating E.M.R.
Controversies in Gastroenterology Endoscopic Submucosal Dissection (E.S.D.) vs. Endoscopic Mucosal Resection (E.M.R.) in Colombia. Advocating E.M.R. Raúl Cañadas Garrido, MD. 1 1 Internist-Gastroenterologist.
A918: Prostate: adenocarcinoma
A918: Prostate: adenocarcinoma General facts of prostate cancer The prostate is about the size of a walnut. It is just below the bladder and in front of the rectum. The tube that carries urine (the urethra)
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
Endoscopic Therapy for Early Esophageal Cancer: EMR and ESD
Endoscopic Therapy for Early Esophageal Cancer: EMR and ESD AATS Toronto April 26, 2014 Lorenzo Ferri MD PhD David S. Mulder Chair in Surgery Associate Professor of Surgery and Oncology Disclosures Olympus
The recommendations made throughout this book are by the National Health and Medical Research Council (NHMRC).
INTRODUCTION This book has been prepared for people with bowel cancer, their families and friends. The first section is for people with bowel cancer, and is intended to help you understand what bowel cancer
Endoscopic mucosal resection for treatment of early gastric cancer
Gut 2001;48:225 229 225 Endoscopic mucosal resection for treatment of early gastric cancer H Ono, H Kondo, T Gotoda, K Shirao, H Yamaguchi, D Saito, K Hosokawa, T Shimoda, S Yoshida Department of Endoscopy
Historical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study
Original Article Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study Sezer Saglam 1, Dursun Bugra 2, Esra K. Saglam 3, Oktar Asoglu 4, Emre
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
Survival analysis of 220 patients with completely resected stage II non small cell lung cancer
窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian
L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
Cytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of pseudomyxoma
Medical Policy Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pseudomyxoma Peritonei and Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal Mesothelioma
A New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY
A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of
Treatment Volume and Technique
RADIATION THERAPY The standard of care for early lesions is surgical resection; however, selected patients with small central lesions may be considered for definitive radiation, particularly when the lesions
Frequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 [email protected] Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD KCHC 8/29/13 52 y.o. F presented with severe pain in the right back and right flank, sharp, 8 out of 10, for 7 days.
YOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.
Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)
Guidelines for the treatment of breast cancer with radiotherapy
London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal
Elective Clinical Target Volumes in Anorectal Cancer: An RTOG Consensus Panel Contouring Atlas
Elective Clinical Target Volumes in Anorectal Cancer: An RTOG Consensus Panel Contouring Atlas 1 2 1 3 1 1 4 R Myerson, M Garofalo, Iel Naqa, R Abrams, A Apte, W Bosch, P Das, L 5 6 7 8 9 Gunderson, T
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
CLINICAL MANAGEMENT OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS OF THE PANCREAS
1 CLINICAL MANAGEMENT OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS OF THE PANCREAS Carlos Fernández-del Castillo, M.D. Associate Professor of Surgery Massachusetts General Hospital Harvard Medical School,
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
Overview of Gynaecologic Cancer
Overview of Gynaecologic Cancer Stuart Salfinger Gynaecologic Oncologist St John of God Hospital King Edward Memorial Hospital Cervical Cancer Cervical Cancer Risk HPV Smoking?OCP Cervical Cancer Symptoms
Hepatocellular Carcinoma Treatment Decision Tree
Treatment Decision Tree Derek DuBay, MD Assistant Professor of Surgery Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery 1 UAB Liver Tumor Clinic Referrals: 205 996 5970 (phone) 205
